Aldeyra Therapeutics, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:ALDX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -12.47 M-8.56 M-7.02 M-5.3 M-5.11 M-4.59 M -22.02 M Cash from investing activities 7.29 M-554.13 K25 M16 M0-23.1 K 40.98 M Cash from financing activities 1 M0120.75 K071.14 K-15.3 M -15.11 M Free cash flow -12.47 M-8.56 M-7.02 M-5.3 M-5.11 M-4.59 M -22.02 M

News

AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down

LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection

Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX)

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims - TipRanks.com

AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV)

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.10%

RBC reiterates Bausch & Lomb stock rating on DED rival delay